



MEDIMAPS
We understand bone health

Trabecular Bone Score (TBS)

A paradigm shift in osteoporosis
assessment and management

Executive summary

Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and the degradation of bone microarchitecture. These dual components — bone mass and bone microarchitecture — underpin the structural integrity necessary for bone resilience against fractures [1]. Traditional densitometric evaluations, centered around a bone mineral density (BMD) T-score of -2.5 or lower, capture the bone mass dimension of this risk, effectively discerning a subset of individuals predisposed to fragility fracture [2,3]. Yet, this approach does not fully address the spectrum of fracture risk, because most of these fractures occur in patients with T-scores outside the osteoporotic range [2-5]. A more comprehensive assessment framework is requisite — one that integrates bone microarchitecture, the second critical determinant of bone strength, to refine the identification of those at increased fracture risk.


In addressing this clinical need, Trabecular Bone Score (TBS) is a pivotal advancement. TBS is an innovative analytic method that derives a grey-level textural index from dual-energy X-ray absorptiometry (DXA) scans, delivering a quantifiable assessment of bone microarchitecture. This index exhibits a strong correlation with the intrinsic microarchitecture and mechanical competencies of bone, thus complementing the BMD T-score and enriching fracture risk assessment [6-11]. Clinical application of TBS has demonstrated its efficacy, either as an adjunctive metric that refines FRAX probabilities and BMD T-scores, or as an independent measure with established clinical cut-off values [12,13].

This white paper elucidates the scientific underpinnings, clinical utility, and the value of TBS in improving osteoporosis management and patient outcomes. It affirms TBS's integral role in a paradigm shift toward more complete and effective fracture risk assessments, therapeutic decision-making and monitoring.

Problem statement: current challenges in osteoporosis

The global burden of fragility fractures is substantial, with around 9 million cases occurring annually, and at least one in three women and one in five men aged over the age of 50 years sustaining an osteoporotic fracture [14]. This equates to one major osteoporotic fracture every 3 seconds [14]. Such fractures, especially those of the hip and spine which are associated with significant pain and disability, bringing substantial burdens for patients, their families and healthcare systems. Of those patients who sustain a hip fracture, around one third will die within 12 months [15,16]. Current trends and demographic shifts predict a rise in the burden of osteoporosis, yet research demonstrates that a large proportion of fractures could be prevented with better risk identification [17,18].

In most cases, osteoporosis remains undiagnosed until a fracture occurs, highlighting the inadequacies of current risk assessment strategies. Although BMD is integral for determining bone mass, it does not address the micro-architectural quality of bone, which is a vital factor for bone strength. It is also noteworthy that over 70% of fragility fractures occur in women who are non-osteoporotic by BMD alone [3,4] (Figure 1) – which highlights a critical imitation of relying solely on BMD for risk stratification.



Source: Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML, et al.
The NORA cohort. Arch Intern Med. 2004;164(10):1108-12.

Figure 1. The majority of fractures occur in individuals who are not osteoporotic by BMD alone, from Siris et al., (2004) [2].

Solution: introduction to trabecular bone score

TBS iNsight™ is an advanced software which enhances DXA system capabilities, by providing a non-invasive validated index of bone microarchitecture, alongside the standard BMD evaluation. The software operates by assessing bone texture and providing a trabecular bone score (TBS) —a quantifiable index that correlates with the micro-architectural status and mechanical properties of trabecular bone.

Utilizing a modified experimental variogram-based approach, the patented TBS algorithm interprets the complexity of the bone's projected image, translating subtle grey-level pixel-by-pixel variations into an estimate of three-dimensional microarchitecture. This process is based on fractal analytics and the calculation of TBS involves determining the slope from a log-log transformation of the modified experimental variograms of the DXA image. Conceptually, a steeper slope indicates a dense and well-connected trabecular pattern, equating to a higher TBS, while a flatter slope signifies greater disconnection and porosity, reflected by a lower TBS (Figure 2). The process requires no additional scan time or radiation exposure for the patient. It is noteworthy that two patients may have comparable BMD but can differ in terms of bone microarchitecture reflected by TBS, predisposing to a different level of fracture risk (Figure 2).




Figure 2. TBS is derived from an algorithm that provides a grey-scale pixel-by-pixel analysis which relates to trabecular microarchitecture and mechanical properties of bone

Clinical evidence

The efficacy of TBS in predicting fragility fracture is underpinned by over one decade of peer-reviewed research. The global research community has contributed to this evidence base with over 1,500 peer-reviewed publications, and the clinical utility of TBS is underscored by its widespread adoption—over 4.5 million TBS evaluations are performed annually across more than 90 countries*[1].

Fracture risk assessment

TBS is established as a significant predictor of fragility fracture among postmenopausal women and men over 50 years of age, independent of BMD and clinical risk factors, including those integrated into FRAX® [19]. This has been consistently demonstrated by over 20 prospective population cohort studies. In addition, an international meta-analysis of 14 population cohort studies showed that FRAX adjusted for TBS resulted in a significant increase in fracture risk prediction, independent of sex and ethnicity [12]. This predictive enhancement is similarly observed when BMD T-score is adjusted for TBS [13].

In the Manitoba cohort of 45,185 postmenopausal women each SD decrease in TBS was significantly associated with a 26%, 25% and 22% greater risk of fragility fracture in models incorporating BMD at the lumbar spine, femoral neck and total hip, respectively, and the results were not attenuated after adjustment for age and BMI [13].

The clinical relevance of TBS extends to secondary osteoporosis, having an important role in the assessment and management of patients with conditions that affect bone health. Degraded TBS is a common finding across most diseases associated with secondary osteoporosis and is associated with an increased risk of fracture, even when BMD is normal [19] (Figure 3). In particular, TBS independently predicts fracture risk in patients with diabetes [20,21], rheumatological diseases [22,23], chronic kidney disease [24,25] and those undergoing long-term glucocorticoid therapy [26,27] or treatment with aromatase inhibitors [28,29] - conditions known to compromise bone integrity [19]. An additional advantage of TBS is its relative insensitivity to certain spinal changes, including the presence of osteophytes and syndesmophytes, which can erroneously increase BMD assessments [30].



Figure 3. Published evidence on the value of TBS for the assessment and management of secondary osteoporosis

Treatment decision-making

Pharmacotherapy for osteoporosis can effectively reduce fracture risk by 30% to 70% [31], highlighting the importance of risk assessment and timely treatment intervention. TBS is a particularly valuable tool in this risk assessment process, especially for patients who are close to a treatment intervention threshold according to FRAX probability or BMD T-score assessments [32], for example, in patients with osteopenia, where the greatest fracture burden is observed [2-4]. In these instances, the addition of TBS can fine-tune risk assessment by determining the necessity and timing of therapeutic intervention, thereby avoiding overtreatment or delaying necessary treatment [19,32].

Treatment monitoring

TBS as an adjunct to BMD, offers insights into changes in bone microarchitecture over time and in response to treatment. Adjusting therapy based on TBS as well as BMD, may help clinicians optimize patient outcomes in the management of osteoporosis. Given that TBS and BMD reflect different entities of bone strength, a differential response to treatment is expected [19]. When interpreting patient results, it is important to align them with the anticipated effects of the treatment molecule. In cases where the results deviate from expectations, it is advisable to check both clinical and technical factors [19].

Evidence demonstrates that while BMD is responsive to anti-resorptive therapies such as bisphosphonates, the effect on TBS appears to be one mostly of preservation [33-35], which is in line with the known treatment mechanism of action [19]. On the other hand, TBS is more responsive to therapies including denosumab, parathyroid hormone agents, and Romosozumab [36-43] (Figure 4).

It is recommended that the monitoring of treatment effect on TBS at the individual level should be made by applying least significant change (LSC). Over 12 studies have published the precision of TBS, which averages at 1.37% and corresponds to a LSC 3.79% [19].




Figure 4. Graphical representation of published changes in TBS and BMD in response to treatment

International positions: enhancing osteoporosis assessment and management

Over 35 national and international clinical guidelines, including the International Society for Clinical Densitometry [44], recommend TBS as a significant predictor of hip and major osteoporotic fractures. The 2023 position paper, published by the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the International Osteoporosis Foundation (IOF) under the WHO Collaborating Centre on Epidemiology of Musculoskeletal Health and Ageing, represents the most comprehensive and updated synthesis of knowledge in the field to date [19]. This document surpasses its predecessors, including the 2015 ESCEO position paper [45] and the ISCD positions [44, 46], in terms of its breadth and depth of analysis. It reflects the expanding evidence base and the increasing global adoption of TBS, marking a significant advancement in the understanding and management of bone health. This comprehensive paper resulted from a series of systematic reviews by an Expert Working Group, appraising evidence from 96 qualifying studies and providing 22 expert statements to guide the use of TBS in clinical practice [19]. The group confirmed the additional value of TBS in fracture risk prediction and the instrumental role of TBS for informing the initiation and monitoring of osteoporosis treatments. The 2023 update emphasized TBS's enhanced utility in clinical decision-making, particularly regarding the choice and usefulness for monitoring long-term pharmacotherapies such as denosumab, and anabolic agents.

Integration into the clinical work flow

With a commitment to both user experience and patient outcomes, TBS technology has undergone regular updates and enhancements. These enhancements have focused on refining features for greater ease of use and seamless integration within existing clinical workflows, for example, with the addition of FRAX-adjusted for TBS curves according to country-specific guidelines. This commitment reflects our recognition of the importance of practicality and efficiency in clinical settings, allowing healthcare professionals to leverage TBS effectively without disrupting their routine patient care processes for the benefit of the patient.




Figure 5. Schematic example of TBS integration into the workflow for osteoporosis assessment and management, from Shevroja et al., (2023) [19]

The fully automatic and DICOM-compatible TBS report is provided simultaneously with the BMD report and enables the assessment of overall bone status and combined risk of fracture, based on FRAX-adjusted for TBS or lowest BMD T-score adjusted for TBS (Figure 6).



Figure 6. TBS report providing an overall assessment of bone status and fracture risk

TBS regulatory clearance and reimbursement

TBS is CE marked as a class 2a medical device, demonstrating compliance with the essential requirements of the relevant European health, safety, and environmental protection legislation. In the United States, TBS was cleared by the Food and Drug Administration (FDA) in 2013, with a subsequent clearance in 2016, affirming its efficacy and safety for clinical use. In 2023, TBS achieved MDR certification, meeting the requirements of the EU Medical Device Regulation, which provides a robust framework for medical device approval in the European Union.

For healthcare providers in the United States, the integration of TBS into patient assessments has been reimbursed since January 1st, 2022, with Medicare providing additional reimbursement for TBS on top of the existing provisions for DXA scans. This reimbursement policy not only facilitates greater access to TBS for patients but also underscores the importance of comprehensive bone health evaluation in clinical practice.

Advancements in TBS

At Medimaps Group, research and innovation drive our mission to elevate patient care. With this commitment at the core of our work, we are proud to introduce TBS Osteo next generation software (version 4), which brings advancements in TBS assessment and clinical usability [47].

A key enhancement in this version is the refined correction for soft tissue thickness anterior to the lumbar spine. Unlike previous iterations that relied on body mass index (BMI) as a surrogate for soft tissue interference, TBS next generation directly measures soft tissue thickness from DXA imaging. This advancement improves precision and expands the applicability of TBS across a broader spectrum of body phenotypes, ensuring assessments are no longer constrained by BMI-based limitations.

The software also introduces a centralized system for managing multiple DXA units with TBS across a hospital network. This capability is particularly valuable for large hospital groups, streamlining workflow efficiency and facilitating consistent, standardized management across different scanning locations.

Additionally, TBS Osteo next generation is available through a subscription model, enabling users to seamlessly benefit from a continuous, exciting evolution of features. With planned annual enhancements, clinical organizations can stay at the forefront of innovation without incurring additional costs, ensuring they always have access to the latest advancements in TBS technology.

Summary

For over ten years, TBS has provided clinicians with additional, valuable insights into bone quality and fracture risk, complementing information provided by BMD and clinical risk factors. With a robust foundation of research and clinical application, TBS has become standard care alongside BMD and FRAX, for many osteoporosis healthcare professionals around the globe.

As a leader in bone health innovation, Medimaps Group continues to advance TBS technology, integrating the latest scientific developments to enhance diagnostic precision and clinical utility. The introduction of TBS Osteo next generation (version 4) exemplifies this commitment, incorporating state-of-the-art soft tissue thickness adjustments and a scalable, centralized platform for hospital networks. These advancements not only strengthen the role of TBS in osteoporosis management today but also set the stage for ongoing innovation, ensuring that healthcare professionals have access to the most advanced tools for optimizing patient care and fracture risk assessment.

Acknowledgements

We extend our appreciation to collaborators worldwide, whose pursuit of knowledge and dedication to clinical excellence have been pivotal in the research and validation of TBS. Our gratitude is also expressed to healthcare professionals who have incorporated TBS into their practices and offered valuable feedback and insights that have helped to steer user enhancements. Recognition is also given to patients who have participated in TBS research over the years and who continue to be the reason for driving higher standards of care in the assessment and management of osteoporosis.

References

- 1.Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD. Intervention thresholds and the diagnosis of osteoporosis. *J Bone Miner Res.* 2015;30(10):1747-1753.
- 2.Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. *Arch Intern Med.* 2004;164(10):1108-1112.
- 3.Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. *Osteoporos Int.* 2006;17:1404-1409.
- 4.Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? *Bone.* 2006;38(5):694-700.
- 5.Binkley N, Morin SN, Martineau P, Lix LM, Hans D, Leslie WD. Frequency of normal bone measurement in postmenopausal women with fracture: a registry-based cohort study. *Osteoporos Int.* 2020;31:2337-2344.
- 6.Pothuau L, Carceller P, Hans D. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. *Bone.* 2008;42(4):775-787.
- 7.Pothuau L, Barthe N, Krieg MA, Mehsen N, Carceller P, Hans D. Evaluation of the potential use of trabecular bone score to complement bone mineral density in the diagnosis of osteoporosis: a preliminary spine BMD-matched, case-control study. *J Clin Densitom.* 2009;12(2):170-176.
- 8.Hans D, Barthe N, Boutroy S, Pothuau L, Winzenrieth R, Krieg MA. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. *J Clin Densitom.* 2011;14(3):302-312.
- 9.Winzenrieth R, Michelet F, Hans D. Three-dimensional (3D) microarchitecture correlations with 2D projection image gray-level variations assessed by trabecular bone score using high-resolution computed tomographic acquisitions: effects of resolution and noise. *J Clin Densitom.* 2013;16(3):287-296.
- 10.Muschitz C, Kocijan R, Haschka J, Pahr D, Kaider A, Pietschmann P, Hans D, Muschitz GK, Fahrleitner-Pammer A, Resch H. TBS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. *Bone.* 2015;79:259-266.
- 11.Ramvalho J, Marques IDB, Hans D, Dempster D, Zhou H, Patel P, Pereira RMR, Jorgetti V, Moyses RMA, Nickolas TL. The trabecular bone score: Relationships with trabecular and cortical microarchitecture measured by HR-pQCT and histomorphometry in patients with chronic kidney disease. *Bone.* 2018;116:215-220.
- 12.McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R, Elders PJ. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. *J Bone Miner Res.* 2016;31(5):940-948.
- 13.Leslie WD, Shevroja E, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D. Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. *Osteoporos Int.* 2018;29:751-758.
- 14.Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int.* 2006;17:1726-1733.
- 15.Moran CG, Wenn RT, Sikand M, Taylor AM. Early mortality after hip fracture: is delay before surgery important? *JBJS.* 2005;87(3):483-489.
- 16.Guzon-Illescas O, Perez Fernandez E, Crespí Villarias N, Quirós Donate FJ, Peña M, Alonso-Blas C, García-Vadillo A, Mazzucchelli R. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. *J Orthop Surg Res.* 2019;14(1):1-9.
- 17.Compston J. Reducing the treatment gap in osteoporosis. *Lancet Diabetes Endocrinol.* 2020;8(1):7-9.
- 18.Fuggle NR, Curtis B, Clynes M, Zhang J, Ward K, Javaid MK, Harvey NC, Dennison E, Cooper C. The treatment gap: the missed opportunities for osteoporosis therapy. *Bone.* 2021;144:115833.

19. Shevroja E, Reginster JY, Lamy O, Al-Daghri N, Chandran M, Demoux-Baiada AL, Kohlmeier L, Lecart MP, Messina D, Camargos BM, Payer J. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. *Osteoporos Int.* 2023;34(9):1501-1529.
20. Leslie WD, Aubry-Rozier B, Lamy O, Hans D, Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. *J Clin Endocrinol Metab.* 2013;98(2):602-609.
21. Yamamoto M, Yamauchi M, Sugimoto T. Prevalent vertebral fracture is dominantly associated with spinal microstructural deterioration rather than bone mineral density in patients with type 2 diabetes mellitus. *PLoS One.* 2019;14(9)
22. Breban S, Briot K, Kolta S, Paternotte S, Ghazi M, Fechtenbaum J, Roux C. Identification of rheumatoid arthritis patients with vertebral fractures using bone mineral density and trabecular bone score. *J Clin Densitom.* 2012;15(3):260-266.
23. Kang KY, Kim IJ, Park SH, Hong YS. Associations between trabecular bone score and vertebral fractures in patients with axial spondyloarthritis. *Rheumatology.* 2018;57(6):1033-1040.
24. Naylor KL, Prior J, Garg AX, Berger C, Langsetmo L, Adachi JD, Goltzman D, Kovacs CS, Josse RG, Leslie WD. Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. *Clin J Am Soc Nephrol.* 2016;11(11):2032-2040.
25. Aleksova J, Kurniawan S, Elder GJ. The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease. *Osteoporos Int.* 2018;29:1447-1455.
26. Chuang MH, Chuang TL, Koo M, Wang YF. Trabecular bone score reflects trabecular microarchitecture deterioration and fragility fracture in female adult patients receiving glucocorticoid therapy: a pre-post controlled study. *Biomed Res Int.* 2017;2017:4763269.
27. Florez H, Hernández-Rodríguez J, Muxi A, Carrasco JL, Prieto-González S, Cid MC, Espinosa G, Gómez-Puerta JA, Monegal A, Gualiabens N, Peris P. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. *Rheumatology.* 2020;59(7):1574-1580.
28. Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, Moon HG, Han WS, Noh DY, Kim SW, Shin CS. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer. *Osteoporos Int.* 2017;28:1413-1422.
29. Mariotti V, Page DB, Davydov O, Hans D, Hudis CA, Patil S, Kunte S, Girotra M, Farooki A, Fornier MN. Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: an enhanced screening approach incorporating trabecular bone score. *J Bone Oncol.* 2017;7:32-37.
30. Hayden AC, Binkley N, Krueger D, Bernatz JT, Kadri A, Anderson PA. Effect of degeneration on bone mineral density, trabecular bone score and CT Hounsfield unit measurements in a spine surgery patient population. *Osteoporos Int.* 2022;33(8):1775-1782.
31. Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. *Drugs.* 2011;71:65-78.
32. Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D, Kanis JA. Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD cohort. *J Bone Miner Res.* 2017;32(7):1568-1574.
33. María RS, Marta PM, Sonia S, Natalia GG, Tamara M, Ignasi T, Maria MG, Jaime RM, Adolfo DP, Joan A, Xavier N. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort. *Bone.* 2016;92:1-8.
34. Prasad C, Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, Van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: a randomized, controlled clinical trial. *Bone.* 2016;90:123-126.
35. Leslie WD, Majumdar SR, Morin SN, Hans D, Lix LM. Change in trabecular bone score (TBS) with antiresorptive therapy does not predict fracture in women: the Manitoba BMD cohort. *J Bone Miner Res.* 2017;32(3):618-623.
36. Di Gregorio S, Del Rio L, Rodriguez-Tolra J, Bonel E, García M, Winzenrieth R. Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS). *Bone.* 2015;75:138-143.
37. Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. *Osteoporos Int.* 2018;29:323-328.

- 38.Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M. Effects of teriparatide and sequential minodronate on lumbar spine bone mineral density and microarchitecture in osteoporosis. *Calcif Tissue Int.* 2017;101:396-403.
- 39.Jeong C, Kim J, Lim Y, Ha J, Kang MI, Baek KH. Effect of Romosozumab on trabecular bone score compared to anti-resorptive agents in postmenopausal women with osteoporosis. *J Bone Metab.* 2021;28(4):317.
40. Hans D, Shevroja E, McDermott M, Huang S, Kim M, McClung M. Updated trabecular bone score accounting for the soft tissue thickness (TBSTT) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis. *Osteoporos Int.* 2022;33(12):2517-2525.
- 41.Sandeep NV, Joseph A, Cherian KE, Kapoor N, Paul TV. Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters. *Ther Adv Endocrinol Metab.* 2022;13:20420188221112903.
- 42.Hans D, McDermott M, Huang S, Kim M, Shevroja E, McClung M. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension. *Osteoporos Int.* 2023;pp.1-10.
- 43.Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B. Effect of abaloparatide on bone microarchitecture assessed by trabecular bone score in women with osteoporosis: post hoc analysis of ACTIVE and ACTIVEExtend. *J Bone Miner Res.* 2023;38(4):464-470.
- 44.Krohn K, Schwartz EN, Chung YS, Lewiecki EM. Dual-energy X-ray absorptiometry monitoring with trabecular bone score: 2019 ISCD official position. *J Clin Densitom.* 2019;22(4):501-505.
- 45.Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi ML, Cooper C, Kendler D, Lamy O, Laslop A, Camargos BM, Reginster JY. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. *Bone.* 2015;78:216-224.
- 46.Shuhart C, Cheung A, Gill R, Gani L, Goel H, Szalat A. Executive summary of the 2023 adult position development conference of the International Society for Clinical Densitometry: DXA reporting, follow-up BMD testing and trabecular bone score application and reporting. *J Clin Densitom.* 2023;101435.
47. Gattineau G, Hind K, Shevroja E, Gonzalez-Rodriguez E, Lamy O, Hans D. Advancing trabecular bone score (TBS): clinical performance of TBS version 4.0 with direct correction for soft tissue thickness—the Osteolaus Study. *Osteoporos Int.* 2025;DOI: 10.1007/s00198-025-07421-4.



MEDIMAPS

We understand bone health

Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment.

Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company's DNA.



swiss made software

For more information, please visit our website www.medimaps.ai © 2026 Medimaps Group. MM-WP-1293-MIG-EN-04--WW. TBS iNsight is a trademark of Medimaps Group. Not all products are available in all global markets. Please refer to your local distributor or agent. Medimaps Group reserves the right to modify the specifications and features described herein or discontinue manufacture of the product described at any time without prior notice or obligation. Please contact your authorized Medimaps representative for the most updated information. Medimaps Group is certified to ISO 13485:2016 (certificate C831121). TBS Insight is FDA 510(k) cleared and MDR compliant, CE-marked under notified body 2460.

CE 2460